Cargando…

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

BACKGROUND: Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhakal, Binod, Sharma, Shruti, Balcioglu, Mustafa, Shchegrova, Svetlana, Malhotra, Meenakshi, Zimmermann, Bernhard, Billings, Paul R., Harrington, Alexandra, Sethi, Himanshu, Aleshin, Alexey, Hari, Parameswaran N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848740/ https://www.ncbi.nlm.nih.gov/pubmed/35186734 http://dx.doi.org/10.3389/fonc.2022.786451

Ejemplares similares

Recent advances in understanding multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2016)

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
por: Loupakis, Fotios, et al.
Publicado: (2021)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics
por: Awada, Hassan, et al.
Publicado: (2021)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study
por: Buradagunta, Christopher Staffi, et al.
Publicado: (2022)

Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation
por: Thapa, Bicky, et al.
Publicado: (2021)

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma
por: Pisano, Michael, et al.
Publicado: (2021)

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
por: Reinert, Thomas, et al.
Publicado: (2019)

ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden
por: Schneider, Charles J., et al.
Publicado: (2021)

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
por: Kleman, Ariel, et al.
Publicado: (2023)

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
por: Dong, Jing, et al.
Publicado: (2022)

Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma
por: Nathwani, Nitya, et al.
Publicado: (2022)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
por: Kasi, Pashtoon M., et al.
Publicado: (2022)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Plegia to walking: AHSCBMT in severe NMOSD relapse
por: Carlisle, Nicola, et al.
Publicado: (2020)

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report
por: Azzi, Georges, et al.
Publicado: (2022)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
por: Garderet, Laurent, et al.
Publicado: (2018)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
por: D'Souza, Anita, et al.
Publicado: (2020)

Pericardial relapse of multiple myeloma
por: Jamison, Lee S, et al.
Publicado: (2020)

Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
por: Lonardi, Sara, et al.
Publicado: (2022)

SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION
por: Freytes, Cesar O., et al.
Publicado: (2013)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Cutaneous involvement in relapsed multiple myeloma
por: Salle, Valéry, et al.
Publicado: (2022)

A Focus on Relapsed Multiple Myeloma
por: Noonan, Kimberly, et al.
Publicado: (2022)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Germline Risk Contribution to Genomic Instability in Multiple Myeloma
por: Janz, Siegfried, et al.
Publicado: (2019)

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study
por: Dhakal, Binod, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n6pggc86u01lk1bsprd0vlchc7